ReviewAnnals of medicine and surgery (2012)2025
Monocyte-to-lymphocyte ratio as a subtype-specific biomarker in breast cancer prognosis: a narrative review.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a biologically diverse condition featuring unique molecular subtypes that affect prognosis and treatment response. The monocyte-to-lymphocyte ratio (MLR), obtained from peripheral blood counts, has surfaced as a potential inflammatory biomarker indicating the equilibrium between tumor-supporting monocytes and antitumor lymphocytes. This review discusses the function of MLR as a subtype-specific biomarker in breast cancer, emphasizing its potential value in forecasting disease advancement, treatment efficacy, and overall patient results. Evidence shows that increased MLR is linked to poor outcomes in various breast cancer subtypes, such as hormone receptor-positive, human epidermal growth factor receptor 2-enriched, and triple-negative breast cancers. The biological basis arises from the dual function of monocytes in promoting tumor-supportive environments and lymphocytes in facilitating immune monitoring. Through the capture of this immunological interaction, MLR acts as a low-risk and affordable method for risk assessment and treatment choices adapted to molecular subtype traits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.